Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
- 30 May 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 17 (8) , 915-926
Abstract
Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well-accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well-designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.Keywords
Funding Information
- EGIS Pharmaceuticals PLC (N/A)
This publication has 78 references indexed in Scilit:
- Current status of biosimilars in the treatment of inflammatory bowel diseasesIntestinal Research, 2016
- Postmarket policy considerations for biosimilar oncology drugsThe Lancet Oncology, 2016
- Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibodyJournal of Internal Medicine, 2015
- Biosimilars: Hope and concernJournal of Oncology Pharmacy Practice, 2015
- Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics, 2015
- A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and SlovakiaExpert Review of Pharmacoeconomics & Outcomes Research, 2015
- Biosimilars: Are They Bioequivalent?Digestive Diseases, 2014
- Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countriesThe European Journal of Health Economics, 2014
- The economic pressures for biosimilar drug use in cancer medicineTargeted Oncology, 2012
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009